Emergent BioSolutions

Emergent BioSolutions

Specialized products to healthcare providers and governments to address. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues1.6b1.8b1.1b1.0b1.1b1.1b1.1b
% growth41 %15 %(37 %)(9 %)3 %8 %-
EBITDA553m514m(34.4m)(67.5m)145m57.6m-
% EBITDA margin36 %29 %(3 %)(7 %)14 %5 %-
Profit305m231m(224m)(760m)(263m)(110m)(112m)
% profit margin20 %13 %(20 %)(74 %)(25 %)(10 %)(10 %)
EV / revenue3.2x1.4x1.2x0.8x0.5x0.7x0.7x
EV / EBITDA9.1x5.1x-39.3x-12.9x3.8x13.5x-
R&D budget235m234m193m111m---
R&D % of revenue15 %13 %17 %11 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$2.0m

Post IPO Debt
N/A

$20.0m

Grant

$14.5m

Grant
*

N/A

Grant
*
N/A

N/A

Post IPO Debt
*
N/A

$250m

Post IPO Debt
Total FundingAUD53.4m

Recent News about Emergent BioSolutions

Edit
More about Emergent BioSolutions
Edit

At Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do.

Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Emergent BioSolutions

Edit
Adapt Pharma
ACQUISITION by Emergent BioSolutions Aug 2018
Cangene
ACQUISITION by Emergent BioSolutions Dec 2013
Microscience
ACQUISITION by Emergent BioSolutions Jun 2005